Mosaiques Diagnostics GmbH   Report issue

For profit Phase 3
Founded: Hannoverisch Munden Germany (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2013
NCT02040441
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

spironolactone (aldactone) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Nephropathies (Phase 3)

Diabetic Retinopathy (Phase 3)

Kidney Diseases (Phase 3)

Retinal Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1